P529: Longer duration of vancomycin prevents recurrence of C. difficile in patients with inflammatory bowel diseaseECCO '18 Vienna
2018
P530: Psychosexual dysfunction in Greek patients with inflammatory bowel disease in remissionECCO '18 Vienna
2018
P531: Tuberculin skin test conversion rate in inflammatory bowel disease patients receiving anti-TNFα agentsECCO '18 Vienna
2018
P532: Efficacy of combination therapy with cyclosporin and vedolizumab in inflammatory bowel diseases refractory to anti-TNF agentsECCO '18 Vienna
2018
P533: Correlation of endoscopic and clinical endpoints during induction therapy in patients with moderate-to-severe Crohn’s disease: Analysis from CELEST studyECCO '18 Vienna
2018
P534: Spontaneous intra-abdominal abscess in Crohn's disease: Efficacy of non-surgical management and prognostic factorsECCO '18 Vienna
2018
P535: The use of therapeutic drug monitoring for infliximab and adalimumab in inflammatory bowel disease: Practice patterns, understanding and interpretationECCO '18 Vienna
2018
P536: Minimally invasive gasless technique for ileocolic resection using an existing McBurney incisionECCO '18 Vienna
2018
P537: Adalimumab: Relevance of drug trough levels and antibodies assessment in the prognosis of Crohn’s diseaseECCO '18 Vienna
2018
P538: Enteral nutrition for the maintenance of remission in adults with inactive Crohn’s disease: A meta-analysisECCO '18 Vienna
2018
P539: Transcriptional changes in mucosal inflammation associated with an autoimmune protocol diet for ulcerative colitisECCO '18 Vienna
2018
P540: Early response as a prognostic factor for vedolizumab: A real-life experience from a single Italian tertiary centreECCO '18 Vienna
2018
P541: Clinical factors associated with discontinuation of combo or monotherapy for Crohn’s disease: A sub-analysis of a prospective randomised clinical trial (DIAMOND study)ECCO '18 Vienna
2018
P542: Infliximab salvage therapy in acute severe ulcerative colitis: A systematic review and meta-analysisECCO '18 Vienna
2018
P543: Higher post-induction infliximab serum trough levels are associated with healing of fistulising perianal Crohn’s disease in childrenECCO '18 Vienna
2018
P544: Histological remission following ozanimod treatment is associated with concurrent clinical remission and endoscopic mucosal healing: Results from the TOUCHSTONE studyECCO '18 Vienna
2018
P545: Antigenic response to CT-P13 and remicade in inflammatory bowel disease patients shows similar epitope recognitionECCO '18 Vienna
2018